- Home
- ESTA vs INBX Comparison
ESTA vs INBX Comparison
Compare ESTA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESTA | INBX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ESTA | INBX |
|---|---|---|
| Price | $61.99 | $72.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $98.00 | ★ $266.67 |
| AVG Volume (30 Days) | ★ 467.3K | 253.8K |
| Earning Date | 10-29-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,208,000.00 | $1,300,000.00 |
| Revenue This Year | $30.22 | N/A |
| Revenue Next Year | $24.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 76.49 | ★ 550.00 |
| 52 Week Low | $47.23 | $57.30 |
| 52 Week High | $97.59 | $155.29 |
Technical Indicators
Market Signals| Indicator | ESTA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 32.33 |
| Support Level | $54.10 | $72.52 |
| Resistance Level | $67.75 | $86.61 |
| Average True Range (ATR) | 3.93 | 7.16 |
| MACD | 0.63 | -1.85 |
| Stochastic Oscillator | 41.24 | 18.47 |
Price Performance
Historical ComparisonAbout ESTA Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.